Cancer

Understanding behavior, responses and evolution of cells aids in oncology efforts

Researchers publish new data on the enzyme glyoxalase II and its role in cellular metabolism

New analysis method from Karolinska Institutet increases the number of proteins that can be analyzed simultaneously

As part of awards grant, Combined Therapeutics will receive in-kind MilliporeSigma products, consultation in downstream processing and more

Trial of GC4419 in combination with stereotactic body radiation therapy improved overall survival in patients with locally advanced pancreatic cancer

The publication identifies a new T cell exclusion mechanism attributed to CD47-SIRPα signaling

amcure and Hinova Pharmaceuticals enter agreement for development, manufacturing and commercialization of AMC303 in Greater China

Evelo Biosciences' orally delivered microbial extracellular vesicles demonstrate potent antitumor effects

Puma Biotechnology has announced interim results from the Phase 2 SUMMIT trial of neratinib

A plethora of immunotherapies, including immune checkpoint inhibitors, T-cell therapy, monoclonal antibodies, and immune system modulators, have been developed in the past several decades to treat growing global incidences of cancer. However, these therapies are not without risk. This webinar will highlight innovative immunotherapeutic strategies using genetic engineering approaches that modify a patient's own immune cells to more precisely target cancers, while concurrently minimizing the risk of adverse responses.